Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma

NCT ID: NCT06044051

Last Updated: 2023-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-26

Study Completion Date

2026-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment.

Exploring and understanding these data is to improve patient care and discover new therapeutic targets.

The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma in Children Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

microbiosme Asthma in infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients

All patients included will be followed for 1 year, every 3 months

Group Type OTHER

Blood sample

Intervention Type OTHER

An additionnal volume of blood will be collected at inclusion and at each follow-up visit

Expectoration

Intervention Type OTHER

Expectoration will be collected at inclusion and at each follow-up visit

Nasopharyngeal swab

Intervention Type OTHER

A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

An additionnal volume of blood will be collected at inclusion and at each follow-up visit

Intervention Type OTHER

Expectoration

Expectoration will be collected at inclusion and at each follow-up visit

Intervention Type OTHER

Nasopharyngeal swab

A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants less than 24 months old
* Follow-up by a pneumo-pediatrician for severe asthma in infants
* Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009)
* Parent informed of the research and having signed consent

Exclusion Criteria

* Prematurity \<32 WA
* Congenital heart disease with significant left to right shunt
* Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans)
* Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization)
* Refusal of bronchial fibroscopy
Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Rouen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

PETAT Hortense

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Rouen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rouen University Hospital

Rouen, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David Mallet

Role: CONTACT

Phone: 02 32 88 82 65

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hortense PETAT

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Petat H, Hassel C, Michel A, Charbonnier C, Plantier JC, Marguet C. Microbiosthma: a prospective study following respiratory microbiota in young children with severe preschool wheezing to better understand their respiratory future. BMC Pulm Med. 2025 Jul 16;25(1):342. doi: 10.1186/s12890-025-03812-9.

Reference Type DERIVED
PMID: 40670979 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023/0091/OB

Identifier Type: -

Identifier Source: org_study_id